BioAge Labs, Inc. financial data

Symbol
BIOA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1445 A South 50 Th Street, Richmond, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -37.7 % -193%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.9M shares
Common Stock, Shares, Outstanding 35.9M shares
Entity Public Float 474M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 35.9M shares +2042%
Weighted Average Number of Shares Outstanding, Diluted 35.9M shares +2042%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.45M USD
Research and Development Expense 11.1M USD +19.2%
General and Administrative Expense 6.79M USD +94.4%
Operating Income (Loss) -16.4M USD -28.4%
Nonoperating Income (Expense) 3.52M USD
Net Income (Loss) Attributable to Parent -71M USD -8.03%
Earnings Per Share, Basic -0.36 USD/shares +95.4%
Earnings Per Share, Diluted -0.36 USD/shares +95.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 257M USD +48%
Marketable Securities, Current 63M USD
Accounts Receivable, after Allowance for Credit Loss, Current 361K USD
Assets, Current 325M USD
Property, Plant and Equipment, Net 929K USD
Operating Lease, Right-of-Use Asset 3.2M USD
Other Assets, Noncurrent 239K USD
Assets 344M USD
Accounts Payable, Current 3.99M USD
Employee-related Liabilities, Current 1.53M USD
Contract with Customer, Liability, Current 8.18M USD
Liabilities, Current 23.7M USD
Contract with Customer, Liability, Noncurrent 3.23M USD
Operating Lease, Liability, Noncurrent 2.56M USD
Liabilities 30.7M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 264K USD
Retained Earnings (Accumulated Deficit) -266M USD
Stockholders' Equity Attributable to Parent 313M USD
Liabilities and Equity 344M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.4M USD -10.8%
Net Cash Provided by (Used in) Financing Activities -1.5M USD -101%
Net Cash Provided by (Used in) Investing Activities -78M USD
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 35.9M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -96.9M USD -164%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 257M USD +45.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 217K USD -49.2%
Deferred Tax Assets, Valuation Allowance 56.1M USD +43.7%
Deferred Tax Assets, Gross 56.1M USD +43.6%
Operating Lease, Liability 3.26M USD
Payments to Acquire Property, Plant, and Equipment 426K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.9M USD +0.48%
Lessee, Operating Lease, Liability, to be Paid 4.56M USD
Property, Plant and Equipment, Gross 1.34M USD
Operating Lease, Liability, Current 700K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 763K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 617K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.31M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 786K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +23.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 810K USD
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 579M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 60K USD +17.6%
Share-based Payment Arrangement, Expense 2.95M USD +246%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares